Invivyd Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Invivyd Inc in the second quarter 2026?
Invivyd Inc recorded a cumulative net loss of $-107 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -59.73%.

Within the Biotechnology & Pharmaceuticals industry 62 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3187 to 3231.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	323.19 %	274.98 %	257.63 %	11.91 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-107	-78	-52	-60	-110
Return On Equity (TTM)	-59.73 %	-53.48 %	-48.65 %	-92.97 %	-177.89 %
IVVD's Total Ranking	# 3231	# 3187	# 2824	# 2238	# 2957
Equity (TTM) in Millions	181	203	242	93	43
Seq. Equity Change	-10.82 %	-15.94 %	159.53 %	117.5 %	-20.98 %
Seq. Net Income Change	-	-	-	-	-

Back to IVVD Management Effectiveness >> IVVD's 5 Years Annual ROE >> Compare IVVD ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 63
Sector	# 451
Overall	# 3231

Return On Equity Statistics
High	Average	Low
-26.74 %	-85.55 %	-177.89 %
(Mar 31 2022)		(Jun 30 2025)

News about Invivyd Inc Return on Equity ROE

Navigating the Path Toward Emergency Use A Balanced Look at Invivyds PEMGARDA Developments

Invivyd, Inc. a biopharmaceutical company based in Waltham, Massachusetts, recently announced a significant publication in The New England Journal of Medicine (NEJM) that underscores a milestone in public health innovation. The publication is a Letter to the Editor that highlights the immunobridging pathway for PEMGARDA (pemivibart), leading to its Emergency Use Authorization (EUA) intended to prevent symptomatic COVID-19. This development marks a pivotal moment for Invivyd as it continues to navigate the complex landscape of pharmaceutical approvals aiming to address the urgent needs posed by viral infectious diseases. Immunobridging Pathway and Correlate of Protection Curve PEMGARDA, a recombinant monoclonal antibody (mAb), stands out due to its potential efficacy against COVID-19. The NEJM letter outlined the immunobridging pathway an approach enabling faster access to promising therapeutics by using existing data from known antibodies to predict the effectiveness of new candidates like pemivibart. This approach is particularly relevant in the evolving field of virology, where timely intervention capabilities are crucial.

IVVD Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	242	68	177	356	558
Y / Y Equity Change	257.63 %	-61.94 %	-50.15 %	-36.21 %	-
Net Income in Millions	-52	-170	-199	-241	-227
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-21.73 %	-251.6 %	-111.93 %	-67.79 %	-40.64 %

Back to IVVD Management Effectiveness >> IVVD's 5 Years Annual ROE >> Compare IVVD ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IVVD's' Return on Equity at Yahoo Finance
IVVD's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IVVD's Competitors
Subscribers only: Roe for Invivyd Inc 's Suppliers
Subscribers only: Return On Equity for IVVD's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T18:19:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.